Amag: Hedge Fund Makes Takeover Bid

by Web Master, Benzinga Editor

August 3, 2011 8:41 AM | 5 seconds read | Make a Comment

MSMB Capital proposes an $18-a-share bid for Amag Pharma to stop a questionable merger with Allos Therapeutics.

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.